EWA
ACTU

EverSource Wealth Advisors’s Actuate Therapeutics ACTU Stock Holding History

EverSource Wealth Advisors’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$95 Buy
35
+33
+1,650% +$137 ﹤0.01% 4278
2025
Q4 		$12 Sell
2
-68
-97% -$467 ﹤0.01% 4246
2025
Q3 		$469 Buy
+70
New +$507 ﹤0.01% 3966

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CCM
Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $237M AUM 5.37% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EverSource Wealth Advisors's ACTU Position: Q1 2026 in Review

EverSource Wealth Advisors increased its Actuate Therapeutics (ACTU) stake by 1,650% in Q1 2026, buying an estimated $137 and bringing the position to 35 shares worth $95. The position accounts for ﹤0.01% of the portfolio, ranked #4278.

EverSource Wealth Advisors first reported a position in ACTU in Q3 2025 and has held it in 3 quarters since. The position peaked at $469 in Q3 2025. 61 funds tracked by Wall St. Rank hold ACTU as of Q1 2026.

  • EverSource Wealth Advisors held 35 shares of Actuate Therapeutics worth $95 as of Q1 2026.
  • EverSource Wealth Advisors bought 33 Actuate Therapeutics shares in Q1 2026, an estimated $137.
  • Actuate Therapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q1 2026, its #4278 holding.
  • EverSource Wealth Advisors first reported a position in Actuate Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • EverSource Wealth Advisors's Actuate Therapeutics position peaked at $469 in Q3 2025.
  • 61 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q1 2026.

Based on EverSource Wealth Advisors's 13F filing for Q1 2026, filed 14 May 2026.